AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05148234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Bone marrow biopsy: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression.
Study NCT05148234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Bone marrow aspiration: required at screening/baseline, Phase I post cycle (C)~1(C1Day(D)28 +/- 3 days) and Phase II post cycle 2 (C2D28 +/- 3 days) and post cycle 6 (C6D28 +/- 3days); and if needed clinically in the setting of aplasia or concern for disease progression.
Study NCT05148234 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: 12-lead electrocardiogram (ECGs) will be performed at baseline only for safety.
Study NCT05164640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: not required
Description: This a multicenter, prospective, non-randomized, single-arm, open label clinical study. This design doesn't include control vs intervention arms
Study NCT05220462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: As per Remimazolam arm
Study NCT04718714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: loading dose intravenous infusion of 0.2 mg/kg over 10 minutes followed by a maintenance dose of 0.02 -0.2 mg /kg/hr. over 24 hours.
Study NCT04718714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: loading dose intravenous infusion of one mg/kg over 15 minutes followed by a maintenance dose of 20-80 microgram/kg/min. over 24 hours.
Study NCT04718714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: loading dose of dexmedetomidine of one µg/kg over 10 minutes followed by maintenance dose of 0.2 -1.5 µg/kg/hr. over 24 hours.
Study NCT05116865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 2
Description: Dose level 2 of HH-120
Study NCT05116865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HH-120 Dose 3
Description: Dose level 3 of HH-120
Study NCT05220462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: As per Midazolam arm
Study NCT04938115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CART
Description: Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis
Study NCT05610384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injectable Solution
Description: ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively
Study NCT05610384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.
Study NCT05093530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neumifil
Description: Neumifil contains the active ingredient HEX17, a multivalent, glycan-targeting carbohydrate binding module (CBM). HEX17 CBM is suspended in an aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
Study NCT05093530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aqueous buffer solution containing 20 mM sodium phosphate, 50 mM NaCl (at pH 6.3), 5 % (v/v) glycerol and 0.5 % (v/v) polysorbate 80.
Study NCT04752891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOM diagnosis with app
Description: the diagnosis made by a senior physician using a traditional otoscope. the diagnosis made by the junior physician using an otoendoscope fixed on a connected smartphone
Study NCT04752891 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: AOM diagnosis without app
Description: the diagnosis made by a senior physician and by the junior physician, using a traditional otoscope
Study NCT05713734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin generation
Description: Measurement of thrombin generation by ST Genesia
Study NCT05713734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrinolysis
Description: Measurement of fibrinolysis by Lysis Timer
Study NCT05713734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibrin clot structure
Description: Measurement of fibrin polymerisation and permeability
Study NCT05713734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coated platelets
Description: Measurement of coated platelets by flow cytometry
Study NCT05206864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Food: SBD111
Description: One capsule administered twice daily with morning and evening meals for 28 days
Study NCT05206864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule administered twice daily with morning and evening meals for 28 days
Study NCT06123572 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT06123572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-Ageing and Skin Brightening Gel
Description: Anti-Ageing and Skin Brightening Gel.
Study NCT05116865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study NCT04772885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-474/Placebo
Description: KT-474 or matching placebo oral tablet(s)
Study NCT04772885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-474
Description: KT-474 oral tablet(s)
Study NCT05677737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational program; It will be applied to the individuals in the experimental group for an average of 40 minutes in a time period they are suitable through the online platform prepared for the individuals in the experimental group in a three-month period. The literature will be scanned and appropriate educational materials will be created, and videos will be used to support education.~Educational program During the first interview, the individuals in the experimental group will be introduced to the online platform, their entrance will be provided, they will be informed about how to follow the trainings, and sample applications will be made.~Six main topics will be covered in the training program and will be completed every two weeks in three months.
Study NCT05512806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Participants will receive AZD5462 orally.
Study NCT06503406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SupraSDRM®
Description: SupraSDRM® Bidegradable Matrix Wound Dressing is a tri-polymber, Biodegrable dermal covering manufactured by PolyMedics Innovations, GmbH.
Study NCT06503406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoSorb® BTM
Description: NovoSorb® BTM absorbable synthetic wound dressing, PolyNovo Biomaterials, K172140
Study NCT05958316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Symptom Capture Tool (C-SCAT) Intervention
Description: The C-SCAT includes the 32 symptoms from the Memorial Symptom Assessment Scale (MSAS). Users select symptoms they have experienced over the past week, rate each symptom's severity and distress, and name a perceived cause. They then identify temporal and causal relationships between symptoms using lines and arrows, designate groups, i.e., clusters of symptoms, and give a name to each cluster. They are asked the reason for a symptom's designation as a priority symptom and what they do to alleviate that symptom. Next, they are asked to designate a priority cluster and finally, to confirm whether the image accurately reflects their symptom experience. Then, at the clinic visit, the AYA shares the visual image with the HCP, and more importantly, their priority symptoms, which can facilitate the symptom discussion. The C-SCAT intervention group will complete the C-SCAT prior to each of three encounters with their health care providers (HCPs).
Study NCT05958316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Usual care is defined as the usual approach to assessing symptoms during the HCP encounter. To provide attentional control to the usual care control group and prevent disproportionate attrition from that group, study staff will contact participants three times during the intervention period (approximately 3 months) when they are in for a scheduled clinic visit and communicate the following: 1) express appreciation for ongoing study participation; 2) ask how everything is going with their treatment; 3) ask if anything has changed with their treatment plan since the last study visit; and 4) confirm continued participation in the study.
Study NCT05839652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Hydrochloride
Description: Determine best drug and dose to increase and stabilize SBP during orthostatic tilt
Study NCT06429215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-component Intervention (MC-I): VR Cognitive training and Psychoeducation on health and lifestyle
Description: In a period of 5 consecutive weeks, participants will receive:~* an interactive immersive virtual reality cognitive training for 30 minutes, 3 days per week. It consists in different tasks implemented in virtual real-like scenarios of daily living situations that target the following cognitive processes: long-term associative memory, relational binding, spatial pattern separation and pattern completion;~* an interactive immersive virtual reality health and lifestyle education program for 30 minutes, 1 day per week. It consists in 360° videos aimed at advancing awareness and knowledge of the various health conditions associated with an increased risk of cognitive decline and dementia and helping participants to develop a healthier lifestyle.
Study NCT06429215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-only intervention (CO-I): VR Cognitive training (+ Psychoeducation active control)
Description: In a period of 5 consecutive weeks, participants will receive:~* the interactive immersive virtual reality cognitive training as described in the MC-I condition, for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for 30 minutes, 1 day per week.
Study NCT06429215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control intervention (AC-I): VR Cognitive active control + Psychoeducation active control
Description: In a period of 5 consecutive weeks, participants will receive:~* an active control of the immersive virtual reality cognitive training (participants will be requested to virtually carry out daily actions, in the same setting as those performed in cognitive immersive VR training, but they will follow prearranged instructions requiring very low cognitive demands) for about 30 minutes, 3 days per week;~* an active control of the immersive virtual reality psychoeducation program for about 30 minutes, 1 day per week.
Study NCT05264792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation Support
Description: This support package will include:~1. one-on-one remote (phone/web-based) technical assistance sessions (every two weeks) between the facility team and the study team Implementation Support Coaches. These sessions will involve a discussion on successes and challenges in integrating depression screening with routine care and developing strategies to improve screening, using the PDSA (Plan Do Study Act) cycle model.~2. remote peer learning community (peers include ANMs and Nurses who administer screening) through a cross-facility WhatsApp group moderated by the study team Coaching Support Team.~3. virtual peer learning network conferences (quarterly) moderated by the Coaching Support Team focused on lessons learned in improving depression screening.~The 9-month intervention duration is informed by the Institute of Healthcare Improvement's Breakthrough Series guidelines.
Study NCT05264792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Implementation Support
Description: This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.
Study NCT05264792 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Implementation Support
Description: This support package will include weekly meetings between District and facility teams, to review and discuss mental health performance indicators, such as depression screening rate, refusal rate for PHQ-2 screening, proportion of referrals of screened positive patients from auxiliary nurse midwife (ANM) to Medical Officer, and rates of diagnosis and initiation of treatment of depression. These indicators will be collated and reviewed by the district team as part of existing non-communicable disease (NCD) care indicators. Monthly performance data will be then emailed by the district team to the facilities, in addition to further data submission reminders. Note that these weekly interactions between the district and facility teams does not include the additional PDSA cycle-based coaching support.
Study NCT06418477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-CyBorD
Description: Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.~Drug: Daratumumab: 16mg/kg IV dose OR 1800 mg subcutaneously Drug: Cyclophosphamide: 300 mg/m\^2 as an oral or IV dose Drug: Bortezomib: 1.3 mg/m\^2 as an subcutaneous (SC) injection. Drug: Dexamethasone: 20-40mg Patients will receive the above drugs (Dara-CyBorD) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 1 years.~Note: If patients achieve less than hematologic VGPR by cycle 3 or less than PR by cycle 2, treatment plan will be allowed to discontinued, according to treatment principle in systemic light chain amyloidosis.
Study NCT06649409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: vamorolone 20 mg/kg single dose on Day 2
Study NCT06649409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone 200 mg single dose on Day 2
Study NCT06649409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.
Study NCT06649409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludrocortisone
Description: Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.
Study NCT06649409 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludrocortisone
Description: Fludrocortisone challenge on Days 1 to 3 (for all subjects):~Day 1:~-Fludrocortisone 1 mg at 9 h predose vamorolone /eplerenone administration/corresponding timepoint for negative control arm~Day 2:~* Fludrocortisone 0.5 mg at the same time of vamorolone/eplerenone administration in the morning (0 h) /corresponding timepoint for negative control arm.~* Fludrocortisone 0.1 mg at 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 14 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~* Fludrocortisone 0.5 mg at 16 h vamorolone/eplerenone postdose administration/corresponding timepoint for negative control arm.~Day 3:~-Fludrocortisone 0.1 mg at 24 h vamorolone/eplerenone postdose administration on Day 2/corresponding timepoint for negative control arm.
Study NCT06590389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mandala activity
Description: A descriptive patient form, VAS and STAI-I were applied before surgery. After the surgery, VAS and STAI-I were applied before and after the mandala activity until the patient was discharged. The VAS form was applied every 4 hours until the patient was discharged. This process was repeated in the same way for the entire intervention group.
Study NCT06590025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INtegral Cognitive REMediation program
Description: This comprehensive functional remediation program includes a traditional CR component with a specialized therapist (based on the compensation model) and a CCT component adapted to the difficulties of each patient. The inclusion of both aspects allows adapting the intervention to the present difficulties by forming new strategies with compensation techniques and promoting translation to everyday life. Therefore, the intervention aims at improving cognitive functioning (beyond a mere training) so as to facilitate the improvement and maintenance of psychosocial functioning for patients with MDD.
Study NCT06590025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for depression
Description: Psycho-education refers to educating individuals about depression and the various treatment options. It is a form of therapy that aims to provide individuals with the knowledge and skills to manage their mental health symptoms effectively.
Study NCT05838339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Sleep Intervention
Description: The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.
Study NCT05838339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Sleep Intervention
Description: The existing intervention consists of the following components: Posters, Instagram, kick-off event, flyer for parents, parents-teacher conference, class discussions, app, classes on sleep (and relaxation), blue lights installations, alarm clocks and t-shirts, T-days without phone in the bedroom (Tuesdays and Thursdays), class competition.
Study NCT06667037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ortho-k lenses
Description: Ortho-k lenses will be administered nightly.
Study NCT06667037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ortho-k lenses
Description: Ortho-k lenses will be administered nightly.
Study NCT06667037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% Atropine
Description: 0.01% Atropine will be administrated twice a day with an interval of about 12 hours. Drop into the conjunctival sac and immediately compress the lacrimal sac of the inner canthus for 2-3 minutes.
Study NCT05398185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleverCap
Description: The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
Study NCT06612099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Individuals in this group will perform aerobic exercise training on a treadmill/bicycle under the supervision of a physiotherapist for a period of 8 weeks, consisting of a total of 24 training sessions. Moderate intensity aerobic exercise training will be set by calculating the target heart rate range. During the training session, individuals will receive a total of 50 minutes of training, consisting of a 10-minute warm-up, 30 minutes of moderate walking/cycling and a 10-minute cool-down period. In addition to the aerobic exercise training group, on the days he does not come to the session, resistance exercises will be taught in the form of 2 sets of 8 repetitions, with weights of 60-80% of 1 maximum repetition, according to the guidelines of the American Sports Medicine Association, and will be given as home exercises.